|
|
|
| Exploration on material basis and mechanism of Bushen Huoxue Decoction in treating multiple myeloma based on network pharmacology and molecular docking technology |
| ZHOU Yanqun LIN Lingyun CHEN Benshu WANG Liqiong LIU Zenghui |
| Department of Hematology, the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Province, Guangzhou 510405, China |
|
|
|
Abstract Objective To explore the effective components and pharmacological targets, signal pathways of Bushen Huoxue Decoction in treating multiple myeloma based on network pharmacology and molecular docking technology. Methods The chemical components of Bushen Huoxue Decoction were searched in traditional Chinese medicine systems pharmacology database and analysis platform. The whole target genes corresponding with the components of Bushen Huoxue Decoction were predicted by searching Swiss Target Prediction database. The gene microarray data of multiple myeloma patients and healthy persons were retrieved from the GEO database by taking “multiple myeloma” as the keyword and compared to screen the differentially expressed genes by the internet analyzer of GEO2R. DAVID database was used for gene ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis of intersection genes. Further, Cytoscape software was used to analyze the network topology parameters, and the core genes and key components were selected according to the degree value, proximity to centrality and intermediary number. Finally, AutoDock Vina was used to verify the molecular docking between core genes and key genes. Results About 97 active components and 98 potential target genes were collected for Bushen Huoxue Decoction corresponding with multiple myeloma therapy. Active ingredients-target network constructed by intersection genes contained 195 nodes and 756 edges. KEGG pathway mainly involved cancer signaling pathway, MAPK signaling pathway and nuclear factor-κB signal transduction pathway, osteoclast differentiation, TNF signal pathway, etc. Molecular docking showed that the key components of Bushen Huoxue Decoction could spontaneously bind to the key targets of multiple myeloma, and the binding performance of methyl cimicifugin with MAPK14 was the best. Conclusion Bushen Huoxue Decoction can inhibit the proliferation of multiple myeloma cells, enhance the effect of chemotherapy and reduce bone damage through multi-component, multi-target and multi-channel. It has a certain value in the treatment of multiple myeloma.
|
|
|
|
|
|
[1] Ludwig H，Bolejack V，Crowley J，et al. Survival and years of life lost in different age cohorts of patients with multiple myeloma [J]. J Clin Oncol，2010，28（9）：1599-1605.
[2] 蓝海.补肾解毒方治疗多发性骨髓瘤的临床疗效及实验机制研究[D].广州：广州中医药大学，2017.
[3] 陈鹏，丘和明，宋爽，等.补肾活血法辅助化疗治疗多发性骨髓瘤骨病16例疗效观察[J].新中医，2006，38（8）：24-25.
[4] 袁海静.补肾活血化瘀方联合化疗对多发性骨髓瘤肾损害的疗效观察[D].广州：广州中医药大学，2018.
[5] 吴青.补肾活血方改善多发性骨髓瘤骨病溶骨性破坏的临床研究[D].广州：广州中医药大学，2018.
[6] 汝锦龙.中药系统药理学数据库和分析平台的构建和应用[D].咸阳：西北农林科技大学，2015.
[7] Daina A，Michielin O，Zoete V. Swiss target prediction：updated data and new features for efficient pharmacology for drug discovery from herbal medicines [J]. J Cheminform，2014（6）：13.
[8] 何思羽，王清.基于生物信息分析学方法筛选多发性骨髓瘤差异表达基因[J].山东医药，2019，59（15）：28-32.
[9] 朱章志，施岚尔，刘江涛，等.基于网络药理学探讨青蒿治疗人急性髓系白血病作用机制[J].中华中医药学刊，2021，39（1）：1-4，259-260.
[10] 徐森楠，庄莉，翟园园，等.基于网络药理学研究二至丸防治骨质疏松症的物质基础与作用机制[J].中国药学杂志，2018，53（22）：1913-1920.
[11] 王露露，李冰，王圳伊，等.基于“整体观”系统生物学技术在中药研究中的应用进展[J].中草药，2020，51（19）：5053-5064.
[12] 卢跃卿.有关名老中医药专家学术思想传承的思考[J].中医药管理杂志，2009，17（7）：595-596.
[13] Nishide Y，Tousen Y，Tadaishi M，et al. Combined effects of soy isoflavones and β-carotene on osteoblast differentiation [J]. Int J Environ Res Public Health，2015，12（11）：13750-13761.
[14] Ahmad KM，Sarwar AHMG，Rahat R，et al. Stigmasterol protects rats from collagen induced arthritis by inhibiting proinflammatory cytokines [J]. Int Immunopharmacol，2020，85：106642.
[15] 赵含笑，于天启.黄芩苷对多发性骨髓瘤细胞株U266增殖、凋亡、侵袭的影响[J].山东医药，2018，58（47）：28-31.
[16] 孟彦彬，孙盛，高巍.牛膝中对成骨样细胞UMR106有促进增殖作用的活性成分研究[J].时珍国医国药，2007， 18（12）：2947-2948.
[17] Hu J，Hu WX. Targeting signaling pathways in multiple myeloma pathogenesis and implication for treatments [J]. Cancer Lett，2018，414（2）：214-221.
[18] 蔺一凡，谷营营，左桂福，等.唑来膦酸盐通过p38 MAPK通路调控高糖条件下破骨细胞分化生成及骨吸收功能[J].南方医科大学学报，2020，40（10）：1439-1447.
[19] Lionetti M，Barbieri M，Todoerti K，et al. Molecular spectrum of BRAF，NRAS and KRAS gene mutations in plasma cell dyscrasias：implication for MEK-ERK pathway activation [J]. Oncotarget，2015，6（27）：24205-24217.
[20] Taniwaki M，Yoshida M，Matsumoto Y，et al. Elotuzumab for the treatment of relapsed or refractory multiple myeloma，with special reference to its modes of action and SLAMF7 signaling [J]. Mediterr J Hematol Infect Dis，2018，10（1）：e2018014.
[21] Boyle EM，Ashby C，Tytarenko RG，et al. BRAF and DIS3 mutations associate with adverse outcome in a long-term follow-up of patients with multiple myeloma [J]. Clin Cancer Res，2020，26（10）：2422-2432.
[22] Yang Y，Fang S. Small non-coding RNAs-based bone regulation and targeting therapeutic strategies [J]. Mol Cell Endocrinol，2017，456：16-35.
[23] 易蓓，袁海汀，许永会，等.NF-κB抑制剂PDTC对人骨髓瘤U266细胞增殖和凋亡的影响[J].中国病理生理杂志，2017，33（7）：1177-1183.
[24] 刘子歌，张晨，宋国瑞，等.白藜芦醇对LPS刺激下RAW264.7细胞向破骨细胞分化的影响[J].医学研究杂志，2020，49（9）：27-31. |
|
|
|
